Suppr超能文献

在瑞典初级保健地区新诊断未治疗的高血压患者中的原发性醛固酮增多症。

Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.

机构信息

Department of General Practice, Lund University, Sweden.

出版信息

Scand J Prim Health Care. 2011 Mar;29(1):57-62. doi: 10.3109/02813432.2011.554015.

Abstract

OBJECTIVE

To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensive patients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR.

DESIGN

Patient survey study.

SETTING AND SUBJECTS

A total of 200 consecutive patients with newly diagnosed and untreated hypertension from six primary health care centres in Sweden were included.

MAIN OUTCOME MEASURES

ARR was calculated from serum aldosterone and plasma renin concentrations. The cut-off level for ARR was 65. Patients with an increased ARR were considered for confirmatory testing with the fludrocortisone suppression test (FST), followed by adrenal computed tomographic radiology (CT) and adrenal venous sampling (AVS).

RESULTS

Of 200 patients, 36 patients had an ARR > 65. Of these 36 patients, 11 patients had an incomplete aldosterone inhibition during FST. Three patients were diagnosed with an aldosterone producing adenoma (APA) and eight with bilateral adrenal hyperplasia (BHA). Except for moderately lower level of P-K in patients with an ARR > 65 and in patients with PA, there were no biochemical or clinical differences found among hypertensive patients with PA compared with patients without PA.

CONCLUSION

Eleven of 200 evaluated patients (5.5%) were considered to have PA. The diagnosis of PA should therefore be considered in newly diagnosed hypertensive subjects and screening for the diagnosis is warranted.

摘要

目的

通过醛固酮/肾素比值(ARR)评估初级保健中初诊和未经治疗的高血压患者中原发性醛固酮增多症(PA)的患病率,并评估ARR 高和正常的患者的临床和生化特征。

设计

患者调查研究。

设置和受试者

共纳入瑞典六个初级保健中心的 200 名连续初诊和未经治疗的高血压患者。

主要观察指标

ARR 由血清醛固酮和血浆肾素浓度计算得出。ARR 的截止值为 65。ARR 升高的患者考虑进行氟氢可的松抑制试验(FST)的确认性检查,随后进行肾上腺计算机断层扫描(CT)和肾上腺静脉取样(AVS)。

结果

在 200 名患者中,有 36 名患者的 ARR>65。在这 36 名患者中,有 11 名患者在 FST 期间醛固酮抑制不完全。3 名患者被诊断为醛固酮分泌腺瘤(APA),8 名患者被诊断为双侧肾上腺增生(BHA)。除了 ARR>65 的患者和 PA 患者的 P-K 水平略低外,PA 患者与无 PA 的高血压患者之间没有发现生化或临床差异。

结论

在评估的 200 名患者中,有 11 名(5.5%)被认为患有 PA。因此,应考虑在初诊的高血压患者中诊断 PA,并应进行诊断筛查。

相似文献

1
Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.
Scand J Prim Health Care. 2011 Mar;29(1):57-62. doi: 10.3109/02813432.2011.554015.
3
High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden.
Scand J Prim Health Care. 2006 Sep;24(3):154-9. doi: 10.1080/02813430600830931.
4
Primary aldosteronism: emerging trends.
Trends Endocrinol Metab. 2013 Sep;24(9):421-30. doi: 10.1016/j.tem.2013.05.003. Epub 2013 Jun 21.
6
Determination of adrenal hypersecretion in primary Aldosteronism without aldosterone-production adenomas.
BMC Endocr Disord. 2021 May 31;21(1):114. doi: 10.1186/s12902-021-00770-1.

引用本文的文献

1
Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension.
Front Endocrinol (Lausanne). 2025 Apr 14;16:1555572. doi: 10.3389/fendo.2025.1555572. eCollection 2025.
2
Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.
Front Endocrinol (Lausanne). 2025 Jan 14;15:1372683. doi: 10.3389/fendo.2024.1372683. eCollection 2024.
3
Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism.
Endocr Connect. 2024 Jan 24;13(3). doi: 10.1530/EC-23-0445. Print 2024 Mar 1.
4
Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care.
Endocrine. 2022 Jun;77(1):11-20. doi: 10.1007/s12020-022-03084-x. Epub 2022 May 27.
5
Primary aldosteronism is a public health issue: challenges and opportunities.
J Hum Hypertens. 2020 Jul;34(7):478-486. doi: 10.1038/s41371-020-0336-2. Epub 2020 Apr 27.
6
Primary aldosteronism.
Gland Surg. 2020 Feb;9(1):14-24. doi: 10.21037/gs.2019.10.23.
7
Outcomes After Surgery for Unilateral Dominant Primary Aldosteronism in Sweden.
World J Surg. 2020 Feb;44(2):561-569. doi: 10.1007/s00268-019-05265-8.
8
Prevalence of primary aldosteronism in primary care: a cross-sectional study.
Br J Gen Pract. 2018 Feb;68(667):e114-e122. doi: 10.3399/bjgp18X694589. Epub 2018 Jan 15.
9
Misdiagnosis of a hidden cause of hypertension: a case report.
Br J Gen Pract. 2017 Dec;67(665):578-579. doi: 10.3399/bjgp17X693869.
10
Primary aldosteronism: a common cause of resistant hypertension.
CMAJ. 2017 Jun 5;189(22):E773-E778. doi: 10.1503/cmaj.161486.

本文引用的文献

1
Evaluation of primary aldosteronism.
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):188-93. doi: 10.1097/MED.0b013e3283390f8d.
2
Long-term effects of surgical correction of adrenal hyperplasia and adenoma causing primary aldosteronism.
Langenbecks Arch Surg. 2010 Feb;395(2):133-7. doi: 10.1007/s00423-009-0498-4. Epub 2009 May 6.
3
Long-term results of laparoscopic adrenalectomy for primary aldosteronism.
J Endocrinol Invest. 2009 Jan;32(1):57-62. doi: 10.1007/BF03345680.
4
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.
J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81. doi: 10.1210/jc.2008-0104. Epub 2008 Jun 13.
5
Primary aldosteronism: an update on screening, diagnosis and treatment.
J Hypertens. 2008 Apr;26(4):613-21. doi: 10.1097/HJH.0b013e3282f4b3e6.
6
Cardiovascular outcomes in patients with primary aldosteronism after treatment.
Arch Intern Med. 2008 Jan 14;168(1):80-5. doi: 10.1001/archinternmed.2007.33.
7
Primary aldosteronism: the case for screening.
Nat Clin Pract Nephrol. 2007 Nov;3(11):582-3. doi: 10.1038/ncpneph0626. Epub 2007 Oct 2.
8
Primary aldosteronism: renaissance of a syndrome.
Clin Endocrinol (Oxf). 2007 May;66(5):607-18. doi: 10.1111/j.1365-2265.2007.02775.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验